Core Viewpoint - The company Maipu Medical is planning to acquire at least 51% of the shares of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of share issuance and cash payment, along with raising supporting funds [1] Group 1: Acquisition Details - Yijie Medical and Maipu Medical share the same actual controller, Yuan Yuyu, who holds 59.19% of Yijie Medical's shares indirectly through various enterprises [1] - Starting from May 2024, Yuan Yuyu will also serve as the chairman of Yijie Medical [1] Group 2: Business Development - Yijie Medical has rapidly developed its neurointerventional business, with a broad range of products for stroke treatment, including ischemic, hemorrhagic, and access products [2] - The first product was approved in 2022, and by May 2025, a total of 12 products are expected to be approved [2] - Yijie Medical is one of the first domestic brands to receive approval for neurointerventional access catheters for radial access indications [2] Group 3: Market Potential - Maipu Medical's core business focuses on neurosurgical repair, and Yijie Medical currently covers over 300 hospitals [3] - In 2024, Yijie Medical is projected to generate a main business revenue of 24.41 million yuan, with a loss of 28.29 million yuan [3] - The acquisition is expected to enhance Yijie Medical's market penetration through Maipu Medical's established channels [3] Group 4: Investment Outlook - Maipu Medical has strong product and channel advantages in the neurosurgical repair field, and the acquisition of Yijie Medical will allow entry into the neurointerventional market [4] - The synergy between Yijie Medical and Maipu Medical's existing business matrix is anticipated to drive new performance growth [4] - Revenue projections for Maipu Medical from 2025 to 2027 are 343 million, 424 million, and 531 million yuan, with corresponding net profits of 97 million, 121 million, and 154 million yuan [4] - The expected EPS for 2025, 2026, and 2027 are 1.46, 1.82, and 2.32 yuan, with PE ratios of 43.93, 35.28, and 27.70 times respectively [4]
迈普医学(301033)：迈普医学收购易介医疗 跨入神经介入行业